GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » Cyclically Adjusted Revenue per Share

Kyorin Pharmaceutical Co (TSE:4569) Cyclically Adjusted Revenue per Share : 円1,855.86 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kyorin Pharmaceutical Co's adjusted revenue per share for the three months ended in Dec. 2023 was 円562.760. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円1,855.86 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Kyorin Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Kyorin Pharmaceutical Co was 3.60% per year. The lowest was 3.00% per year. And the median was 3.00% per year.

As of today (2024-05-24), Kyorin Pharmaceutical Co's current stock price is 円1688.00. Kyorin Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was 円1,855.86. Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 0.91.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kyorin Pharmaceutical Co was 1.82. The lowest was 0.91. And the median was 1.17.


Kyorin Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,606.08 1,632.61 1,690.42 1,786.91 -

Kyorin Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,786.91 1,810.16 1,837.91 1,855.86 -

Competitive Comparison of Kyorin Pharmaceutical Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.



Kyorin Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kyorin Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=562.76/106.8000*106.8000
=562.760

Current CPI (Dec. 2023) = 106.8000.

Kyorin Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 374.346 95.700 417.765
201406 353.298 98.000 385.023
201409 330.781 98.500 358.654
201412 434.841 97.900 474.372
201503 396.718 97.900 432.783
201506 359.145 98.400 389.804
201509 348.726 98.500 378.111
201512 500.553 98.100 544.945
201603 405.754 97.900 442.641
201606 377.341 98.100 410.805
201609 365.402 98.000 398.214
201612 437.163 98.400 474.482
201703 388.142 98.100 422.564
201706 359.733 98.500 390.046
201709 330.060 98.800 356.786
201712 436.597 99.400 469.100
201803 375.803 99.200 404.594
201806 340.607 99.200 366.702
201809 341.616 99.900 365.211
201812 544.430 99.700 583.201
201903 550.220 99.700 589.403
201906 449.489 99.800 481.016
201909 393.639 100.100 419.986
201912 529.187 100.500 562.360
202003 547.576 100.300 583.062
202006 430.978 99.900 460.745
202009 402.241 99.900 430.023
202012 475.027 99.300 510.905
202103 487.741 99.900 521.429
202106 430.962 99.500 462.580
202109 425.929 100.100 454.438
202112 499.363 100.100 532.787
202203 485.175 101.100 512.529
202206 429.636 101.800 450.738
202209 427.098 103.100 442.425
202212 551.689 104.100 565.998
202303 568.250 104.400 581.313
202306 486.074 105.200 493.467
202309 472.191 106.200 474.859
202312 562.760 106.800 562.760

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Kyorin Pharmaceutical Co  (TSE:4569) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1688.00/1855.86
=0.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kyorin Pharmaceutical Co was 1.82. The lowest was 0.91. And the median was 1.17.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kyorin Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyorin Pharmaceutical Co (TSE:4569) Business Description

Traded in Other Exchanges
N/A
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines